UPDATE: Ultragenyx Pharma (RARE) Sees Intra-Day Weakness
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Up)Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - February 10, 2021 10:43 AM EST)
Ultragenyx Pharma (NASDAQ: RARE) sees mid-day weakness, shares down 1.7%.
UPDATE: Weakness said related to FDA FAERS database showing Dojolvi drug has lead to several recent deaths.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Companies with NDRs 4/09
- Second Sight Medical (EYES) on watch following positive research mention at Keck School of Medicine
- EU Seeks New Contract With Pfizer (PFE)/BioNTech SE (BNTX) For Up To 1.8 Billion Covid-19 Vaccines To Be Delivered In 2022, 2023 - Reuters
Create E-mail Alert Related Categories
Trader TalkRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
